文献速递生殖医学

口服地屈孕酮预处理卵巢刺激方案与GnRH拮抗剂方案在胚胎植入前非整倍体遗传学检测周期中的整倍体率比较

Euploidy rates among preimplantation genetic testing for aneuploidy cycles with oral dydrogesterone primed ovarian stimulation or GnRH antagonist protocol.
PubMed 文献 · Reprod Biomed Online · 2022-03-08

这项回顾性队列研究比较了口服地屈孕酮预处理卵巢刺激方案与灵活GnRH拮抗剂方案在PGT-A周期中的整倍体率。共纳入780个周期,经倾向性匹配后每组各390个周期,两组整倍体率无显著差异。作者认为在冻胚全胚冷冻PGT-A周期中,外源性孕激素抑制排卵可视为有效方式。

要点

  • 匹配后地屈孕酮组与拮抗剂组各390个周期,两组整倍体率无显著差异。
  • 仅部分周期形成可活检囊胚并接受二代测序检测,地屈孕酮组262个周期、拮抗剂组263个周期。
  • 按年龄分层并控制PGT-A检测方式后,两组整倍体率仍无显著差异。

核心结论

  • 在冻胚全胚冷冻PGT-A周期中,外源性孕激素抑制排卵可视为有效方式,因其有效性和已知的安全性提升。

研究设计与样本

  • 回顾性队列研究,纳入2017年11月至2019年5月期间首个PGT-A周期的患者,按年龄、BMI和AMH以1:1比例进行倾向性匹配。
  • 共纳入780个周期,地屈孕酮组390个周期,GnRH拮抗剂组390个周期。

主要发现

  • 两组患者基线和周期特征无显著差异。
  • 两组获卵数、MII卵数、活检胚胎数和胚胎检测数均无统计学差异。
  • 因地屈孕酮组仅262个周期、拮抗剂组仅263个周期形成可活检囊胚并接受二代测序检测,每活检胚胎的整倍体率无显著差异。
  • 按年龄分层并控制PGT-A检测方式后,两组间无显著差异。

临床怎么用

  • 作者认为,在冻胚全胚冷冻PGT-A周期中,外源性孕激素抑制排卵可视为有效方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Do differences exist in euploidy rates in preimplantation genetic testing for aneuploidy (PGT-A) cycles with oral dydrogesterone primed ovarian stimulation protocol or the flexible gonadotropin-releasing hormone (GnRH) antagonist protocol? DESIGN: A retrospective cohort study. Patients received the oral dydrogesterone or the GnRH antagonist in the first PGT-A cycle between November 2017 and May 2019. Propensity matching was used to identify a propensity-matched antagonist group based on age, BMI and AMH with a 1:1 ratio. The primary outcome was the rate of euploid embryos. RESULTS: A total of 780 cycles were included, consisting of 390 cycles receiving dydrogesterone and 390 cycles receiving GnRH antagonist protocol. No significant difference was found in patient baseline and cycle characteristics in the two groups. No statistical difference was found in the number of oocytes retrieved, metaphase II oocytes, embryos biopsied and embryo testing between the two groups. As no biopsy blastocysts formed in some cycles, only 262 cycles in the study group and 263 cycles in the antagonist group received next-generation sequencing testing, respectively. Similar to our overall data, the euploid rate per embryo biopsied was not significantly different. No significant differences were found between the two groups after stratifying by age and controlling for PGT-A testing modality. CONCLUSIONS: Ovulation inhibition by exogenous progestins in ovarian stimulation cycles should, therefore, be considered a valid modality in freeze-all PGT-A cycles, in view of its demonstrated effectiveness and known safety enhancement.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Yang L, Luo K, Lu G, et al. Euploidy rates among preimplantation genetic testing for aneuploidy cycles with oral dydrogesterone primed ovarian stimulation or GnRH antagonist protocol. Reprod Biomed Online. 2022. PMID: 35989167. doi:10.1016/j.rbmo.2022.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。